Skip to content
value.today

Alkermes plc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 9.9% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $6.7 B means free cash flow growing 4.3% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew 9.9% a year over the last three years.

Cash-flow value of the shares
$9.9 B
+48% against the market value
Value of the whole business
$9.5 B
before net debt
Value from after year 10
57%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →4.9%7.4%9.9%12.4%14.9%
8.15%+41%+70%+105%+148%+199%
9.15%+20%+44%+72%+107%+148%
10.15%+4%+24%+48%+77%+111%
11.15%-7%+9%+29%+54%+83%
12.15%-17%-2%+15%+36%+60%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Biotechnology: $2.3 B to $14.2 B, median $4.8 BPrice to salesPrice to sales of Biotechnology: $3.3 B to $15.0 B, median $7.3 BPrice to bookPrice to book of Biotechnology: $5.6 B to $23.5 B, median $8.4 BCash-flow value$0 M$6.3 B$12.7 B$19.0 B$25.3 BMarket value $6.7 B

Your own DCF model

A full discounted-cash-flow model of Alkermes plc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Alkermes plc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Alkermes plc.Applied toValue (25th to 75th)Companies
P/E9.4× / 20.0× / 58.8×—net income $242 M$2.3 B to $14.2 B34
Price to sales2.2× / 5.0× / 10.2×3.8×revenue $1.5 B$3.3 B to $15.0 B84
Price to book3.1× / 4.6× / 12.9×3.7×book equity $1.8 B$5.6 B to $23.5 B69

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Alkermes plc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

101.0×

Now above its median of 15.2×, in the top quarter of its range; range 12.6× to 109.8× over 24 months.

0×27×55×82×110×20252026P/E 101×Median 15×

Price to sales

4.0×

Now above its median of 3.5×, in the top quarter of its range; range 2.7× to 5.6× over 30 months.

0×1×3×4×6×2020202120222023202420252026Price to sales 4×Median 3×

Price to book

3.7×

Now close to its median of 3.6×; range 2.7× to 4.8× over 30 months.

0×1×2×4×5×2020202120222023202420252026Price to book 4×Median 4×

as of Oct 14, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 14, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$1.5 B$242 M$521 M$40 M$480 M$-389 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$1.6 B$367 M$439 M$33 M$406 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$1.7 B$356 M$401 M$48 M$353 M$-170 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$1.1 B$-158 M$21 M$38 M$-17 M$-2 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$1.2 B$-48 M$102 M$28 M$74 M$-45 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$1.0 B$-111 M$83 M$42 M$41 M$-1 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $6.7 B on Oct 14, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.